AXIM Biotech to Attend BioCentury’s 25th Annual Future Leaders in the Biotech Industry Conference in New York

NEW YORK, March 21, 2018 -- AXIM^® Biotechnologies, Inc. (AXIM^® Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, today announced that George E. Anastassov, MD, DDS, MBA and Chief Executive Officer of AXIM Biotech, is scheduled to meet with business prospects and investors at BioCentury’s annual Future Leaders in the Biotech Industry Conference on March 23, 2018, at the Millennium Broadway Hotel & Conference Center in New York City.

Now in its 25^th year, the BIO CEO & Investor Conference is one of the largest investor conferences focused on established and emerging publicly traded and select private biotech companies.

“Events like this offer the perfect venue for AXIM Biotech to showcase and educate prospects, the news media and the public on the company’s unique accomplishments within the pharmaceutical cannabinoid space,” Anastassov said.

AXIM Biotech’s presentation for the event is available at this link.

About AXIM

AXIM^® Biotechnologies, Inc. (OTC:AXIM) focuses on the research, development and production of cannabinoid-based pharmaceutical, nutraceutical and cosmetic products. Our flagship products include CanChew Plus^®, a CBD-based controlled release chewing gum containing 10 mg of hemp-derived CBD, CanChew+ 50^®, containing 50 mg of CBD undergoing clinical trials in patients with IBS and MedChew Rx, a combination CBD/THC gum that is undergoing clinical trials for the treatment of pain and spasticity associated with multiple sclerosis. We prioritize the well-being of our customers while embracing a solid fiscal strategy. For more information, please visit AXIMBiotech.com.

FORWARD-LOOKING DISCLAIMER

This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Axim Biotechnologies, Inc. to be materially different from the statements made herein.

LEGAL DISCLOSURE
AXIM^® Biotechnologies does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA).

Public Relations Contact
Andrew Hard
Chief Executive Officer
CMW Media
[email protected]
P. +1888 829-0070
www.cmwmedia.com

Investor Relations Contact
Shiwei Yin, Grayling
[email protected]
P. +1646 284-9474
Lucia Domville, Grayling                                                                                   
[email protected]
P. +1646 284-9416

Corporate Contact Info
North American Address:
45 Rockefeller Plaza, 20^th Floor, Suite 83
New York, NY 10111
+1 844 294 6246

European Address:
Boelewerf 32, Unit 3
2987 VD Ridderkerk, The Netherlands
+31 10 8209 227